A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
=================================================================================================================================================================================================

* Alexandra S. Zimmer
* Erin Nichols
* Ashley Cimino-Mathews
* Cody Peer
* Liang Cao
* Min-Jung Lee
* Elise C. Kohn
* Christina M. Annunziata
* Stanley Lipkowitz
* Jane B. Trepel
* Rajni Sharma
* Lekha Mikkilineni
* Margaret Gatti-Mays
* William D. Figg
* Nicole D. Houston
* Jung-Min Lee